Bolt Biotherapeutics (BOLT) stock has been underperforming, with a 43.2% decline in 2024 and mixed earnings results. Despite beating revenue estimates in Q3 2024 at $1.14 million, the company missed EPS expectations and continues to face financial challenges. Analysts currently rate the stock as "Hold," reflecting limited upside potential and alignment with market performance.